299 results about "Neurotrophic factors" patented technology

A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and / or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and / or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining methyl metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurological function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and / or a cognitive retraining program, and / or a dietary program designed to maximize insulin and glucose metabolism.

A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.

The invention relates to polypyrrole biological conductive hydrogel, as well as a preparation method and application thereof. The preparation method comprises the following steps; preparing carboxymethylchitosan hydrogel from carboxymethyl chitosan by using a crosslinking agent under a certain condition, and performing freeze-drying treatment; performing electrochemical synthesis on a pyrrole monomer to obtain polypyrrole, adding a dopant into the polypyrrole to perform modification and performing ball-milling and crushing to enable the particle size to be matched with the pore diameter of pores of the carboxymethylchitosan hydrogel; blending nerve growth factors into water, adding modified polypyrrole particles, stirring and dispersing uniformly, putting the carboxymethylchitosan hydrogel to enable the solution to be completely absorbed, adding water, vibrating, and completely swelling and balancing to obtain the polypyrrole biological conductive hydrogel. When the polypyrrole biological conductive hydrogel is applied to neural restoration, sustained release of neurotrophic factors can be completed, nerve cells can be subjected to certain electrical stimulation through bioelectrical or external electrical stimulation, proliferation and differentiation of the nerve cells are promoted through double effects of electric stimulation and neurotrophic factor induction, and nerve axon growth is guided.

An application of a phthalide compound in preparing a medicament. The medicament is specially used for promoting a stem cell to secrete one of the following items: telomerase, a neurotrophic factor (brain-derived neurotrophic factor, BDNF), a stem cell chemotactic factor (stromal cell-derived factor-1, SDF1), a stem cell chemotactic factor receptor (CXC chemokine receptor 4, CXCR4), and an immunoregulatory factor; a kit comprising a phthalide compound and a stem cell is also provided.

A method of treatment of neurodegenerative diseases using neuronal cell transplants is provided. The growth, survival and integration of the transplanted neuronal cells is enhanced by a method of culturing the neuronal cells with drugs having an affinity for immunophilins. Immunophilin binding drugs are optionally administered to the patient during transplantation and / or post-operatively. Neurotrophic factors can also be administered to the neuronal cells in vitro, or to the patient during the transplantation procedure and / or post-operatively.

It is intended to provide a novel therapeutic method for a disease with apoptotic degeneration in eye tissue cells such as retinal pigment degeneration. Attention was paid on the concomitant administration of two neurotrophic factors: pigment epithelium-derived factor (PEDF) and fibroblast growth factor 2 (FGF2). The sites of actions are considered to be different between PEDF and FGF2. An SIV-PEDF vector and an SIV-FGF2 vector were constructed and administered to the subretinal space of an RCS rat, which is a disease model of retinal pigment degeneration, and their effects were evaluated. At 4 weeks, 8 weeks and 12 weeks after the administration of the vectors, a significantly higher visual cell protection effect was obtained in a group with concomitant administration than in a group with sole administration. Further, the functional evaluation of retina was carried out by electroretinogram and an effect in the group with concomitant administration was significantly higher than in the group with sole administration. From the above results, it was found for the first time that the concomitant administration of PEDF and FGF2 has higher effects in the treatment of retinal pigment degeneration than conventional methods.